MediSieve, a UCL spin-out, is revolutionising healthcare with its Magnetic Blood Filtration platform. This cutting-edge technology enables precise removal or isolation of harmful substances from the bloodstream, addressing critical challenges across multiple therapeutic areas. Currently focused on AAV gene therapies, MediSieve’s innovation expands patient eligibility and enables redosing, solving major barriers in gene therapy.